SCHEMBL25434048

SCHEMBL25434048

COc1ccc(-c2noc(N3CCC(C(=O)N[C@H]4CCN(Cc5ccccc5)C4)CC3)n2)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.66
▸ TDP1 Q9NUW8 1/20 0.61
▸ MEN1 O00255 4/20 0.60
▸ KMT2A Q03164 4/20 0.60
▸ LMNA P02545 2/20 0.60
▸ MAPT P10636 2/20 0.57
▸ HDAC3 O15379 1/20 0.55
▸ HDAC4 P56524 1/20 0.55
▸ HDAC7 Q8WUI4 1/20 0.55
▸ HDAC9 Q9UKV0 1/20 0.55
▸ HDAC5 Q9UQL6 1/20 0.55
▸ NCOR2 Q9Y618 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25434051 1.00 SMN1; SMN2 (0.66) SMN1; SMN2TDP1MEN1KMT2ALMNA
SCHEMBL30585004 0.87 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL31546397 0.87 MEN1 (0.60) SMN1; SMN2TDP1MEN1KMT2ALMNA
SCHEMBL30584711 0.85 SMN1; SMN2 (0.78) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL31546455 0.82 SMN1; SMN2 (0.77) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL31546432 0.81 MEN1 (0.67) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL30584721 0.81 SMN1; SMN2 (0.74) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL25437981 0.80 LMNA (0.59) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL31546325 0.80 MEN1 (0.59) SMN1; SMN2MEN1KMT2ALMNAMAPT
SCHEMBL30585033 0.80 LMNA (0.59) SMN1; SMN2MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 SMN1; SMN2 3115/4885TDP1 3354/4885MEN1 1569/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 SMN1; SMN2 3115/4885TDP1 3354/4885MEN1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback